This study aims to demonstrate that either selective SGLT1 inhibition (SGLT1i) or dual SGLT1/2 inhibition (SGLT1/2i) could be beneficial in treating diseases associated with SNS activation, such as diabetes and hypertension, and that skeletal muscle may be a target organ for these therapies. This evidence concerns the gene SLC5A1 and diabetes mellitus.